Protecting biological inventions can be difficult, particularly as the legal landscape for that discipline changes.
Our attorneys are at the forefront of developing creative strategies for obtaining the maximum available protection.
Biological products, or biologics, include blood and blood components, organs, tissues, somatic cells, antibodies, and recombinant therapeutic proteins. Therapies, such as immunotherapy, involve the use of biologics as well.
Immunotherapy includes the treatment or prevention of diseases or disorders through inducing or altering an immune response. For example, immunotherapies can elicit or amplify an immune response or can reduce or suppress an immune response.
Hamilton Brook Smith Reynolds has significant patent experience with biologics and immunotherapies, including:
- Antibody-drug conjugates
- Fusion proteins
- Gene therapy
- Methods of manufacturing biologics
- Treatment and prevention of immune disorders
- Use of antibodies to target cells
We have deep experience in the patent prosecution of biologics and immunotherapy inventions including commercial products, as well as in litigation and administrative adversarial proceedings such as interferences, reexaminations, and European opposition proceedings. We also have extensive knowledge regarding the international patenting of biologics and related issues, including biosimilars. Our team has assisted in successfully obtaining supplementary protection certificates extending European patent terms for biologics. We can provide strategic intellectual property counseling on biosimilars. Our experts have been invited to present at national and international conferences on antibodies, biosimilars, and related biotechnology topics. Our firm is also able to handle litigation needs in the area of biologics and immunotherapies.
- Counseled a start-up biologics company in a licensing agreement with a major university covering a joint research project and associated development of intellectual property rights.
- Represented a biotechnology patent owner in an infringement action involving special assays technology resulting in the defendant ceasing all infringing activity.